Palisade Bio, Inc. (NASDAQ: PALI) will present data on PALI-2108, a locally bioactivated PDE4 inhibitor prodrug, for the treatment of fibrostenotic Crohn's disease (FSCD) at the New York Academy of Sciences (NYAS) symposium. The presentation, scheduled for June 9, 2026, in New York, NY, will address the unmet need in FSCD and the biological mechanisms underlying intestinal fibrosis. Mitchell Jones, MD, PhD, President and Chief Medical Officer of Palisade Bio, will lead the session, titled "Locally Bioactivated PDE4 Inhibitor Prodrug for the Treatment of Fibrostenotic Crohn's Disease (FSCD)."

The symposium, titled "Molecular Pathways and Cellular Players in the Resolution of Organ Fibrosis," will convene experts from academia, industry, and clinical research to discuss advances in fibrosis biology and emerging therapeutic strategies. Dr. Jones will emphasize the scientific rationale for PALI-2108 and preclinical findings supporting PDE4 inhibition as a strategy to modulate inflammatory and fibrotic pathways in FSCD.

"Fibrosis remains one of the most significant challenges facing patients with Crohn's disease, yet there are currently no approved therapies specifically designed to address FSCD," said Dr. Jones. "We are honored to participate in this important scientific meeting and look forward to contributing to the broader discussion surrounding fibrosis biology and emerging therapeutic strategies."

PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for selective bioactivation in the ileum and colon, enabling targeted PDE4 inhibition at disease sites. The drug has shown positive results in Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and FSCD. Palisade Bio is now advancing toward Phase 2 clinical studies in UC and Crohn's disease.

Key Details of the Presentation

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. The company's precision pharmacology strategy aims to transform proven PDE4 biology into safer, more effective oral therapies.